Mushrooms,
Inc. (OTC: MSRM) Announces Diverse Business Development Team
Assembled to Drive Company Growth.
ESTERO, Fla.
-- August 23, 2023 -- InvestorsHub NewsWire
-- Mushrooms
Inc. (OTC:MSRM)
- Mushrooms Inc.,
proudly introduces its newly-formed Business Development Team,
strategically assembled to harness the momentum generated by the
company's new technology and Innovation lab development. Comprising
accomplished professionals with diverse backgrounds, this team is
poised to catapult Mushrooms Inc. into a new era of innovation and
growth.
Dr. Reid
Jilek's inclusion reflects Mushrooms Inc.'s
commitment to synergizing academic prowess with industry
innovation. Holding advanced degrees in medical, life sciences, and
engineering, Dr. Jilek has published extensively in national and
international scientific journals. He was both a Presidential
Fellow and a White House Fellow Candidate. Dr. Jilek has developed
in excess of 10,000 professional contacts worldwide in the
healthcare industry and investment world. His leadership roles in
private and public companies, combined with a network spanning the
healthcare industry, establish him as a bridge between academia and
business growth.
Alicia M.
Fantozzi brings
over two decades of international corporate and structured finance
experience to the team. With a focused track record of driving
growth and fostering strategic alliances, her appointment resonates
with Mushrooms Inc.'s vision. Having held key roles in strategic
initiatives, Alicia's extensive experience uniquely equips her to
lead the team's efforts in expanding market presence and revenue
streams.
Her role as Principal at ReGen
establishes a seed-stage idea lab for biomimicry-based regenerative
technologies for water and agriculture., with a concentrated focus
on arranging
financing, field trials and propagation of advanced innovation
initiatives and evaluating complimentary environmental technologies
for international sustainability initiatives, Food, Water &
Natural Resource Security. Her background, strategic acumen, and
commitment to sustainable business practices resonate with
Mushrooms Inc.'s mission of revolutionizing the mushroom
industry.
Dr. Hyder
Khoja, is a
leading figure in the life sciences field with over 22 years of
expertise spanning drug discovery, developmental science, and
policy innovation. Holding a Ph.D. in "Molecular Biology" from
INP-ENSAT and post-doctoral training at Michigan State University,
his education grounds his visionary approach. Dr. Khoja is a
distinguished scientist and visionary in the psychedelic sector,
who brings a profound focus to the team. Notably, he is personally
committed to pioneering the resurrection of coma patients using
psilocybin, adding a transformative dimension to Mushrooms Inc.'s
initiatives in the psychedelic space. Dr. Khoja is senior lead
scientist in the Company's patent pending Mycelium thread project
showcasing the vast background that he brings in support of diverse
projects.
David
Flores, CEO of
PSYC Corporation which owns and operates Psychedelic Spotlight, an
industry-leading media authority for the psychedelic sector, brings
his visionary leadership to the team. His strategic thinking and
experience in the psychedelic landscape perfectly aligns with
Mushrooms Inc.'s aspirations for developing multiple facets of the
Mushroom sector. His marketing expertise and industry knowledge is
integral to the Company as it evolves.
"This enhanced Business Development
Team represents a pivotal milestone for Mushrooms Inc.," said
Donald Steinberg, Board Director of Mushrooms Inc. "As we make
strides in the mushroom sector, our team's collective experience
and expertise provide a robust foundation for innovation and
growth."
"We are delighted to introduce our
exceptional Business Development Team," said Kimberly Zawi Carlson,
CEO of Mushrooms Inc. "I've had the privilege of collaborating with
these amazing individuals over the past months and I feel that they
will collectively bring to Mushrooms Inc what is needed to step
forward. I'm honored to announce a formal collaboration with these
remarkable and versatile professionals. This strategic step is a
direct response to the increasing interest surrounding our
patent-pending technology and the forthcoming revenue-generating
innovation lab. Alicia Fantozzi, Dr. Reid Jilek, David Flores, and
Dr. Hyder Khoja each possess a distinctive skill set that will play
a pivotal role in steering our company's growth trajectory. Their
combined expertise will propel us forward and better address the
investor interest and potential collaborations as we navigate the
exciting opportunities ahead."
About
Mushrooms Inc. (MSRM)
Mushrooms Inc. is a publicly
traded company on the OTC Markets with the stock symbol MSRM.
The
vision for Mushrooms, Inc. is to support the growth of the mushroom
industry through collaboration, innovation and development.
Creating and supporting environmentally beneficial product
innovation is at the heart of Mushrooms, Inc. Our current focus is
on the industrial application of Mycelium for the creation of
carbon-neutral products for the building and health care industries
as well as creating supplements based on the proven health benefits
of mushrooms. Research and Development is the path to achieving
great innovation, and the pioneers are the ones we look to for
their fortitude and enduring dedication to the world of mycology.
The working relationships we foster will result in scientifically
proven products that advance the health of body, mind, and
environment.
About
Dr. Reid Jilek
Dr. Jilek has advanced degrees in
both the medical, life science and engineering disciplines. He was
both a Presidential Fellow and a White House Fellow Candidate. He
has published over 40 papers in national and international
peer--reviewed scientific journals.
After completing his National
Library of Medicine Post-Doctoral developing computer and
mathematical models for Malaria, he decided to utilize his medical
and scientific background in a business development capacity by
acting as a VP of Business Development for private and public
companies and a research institute.
Dr. Jilek has developed in excess of
8,000 professional contacts worldwide in the healthcare industry
and investment world, to include: therapeutics, diagnostics,
vaccines, gene therapy, medical devices, preclinical and clinical
contract research organizations, nutraceuticals, generics,
telemedicine, botanical, and biotech products, as well as the
venture capital and investment banking industries.
He was a founding member of
Frederick Research Center and of Asia Pacific Alliance Company. He
has served on the Board of Directors, Scientific or Medical
Advisory Boards, or Advisory Boards for more than 40 private and
public companies since 1990, in the US, Canada, Mexico, Japan,
Taiwan, China, Portugal, Moscow, Israel and Germany. He has also
served as the CEO of four companies.
About
Alicia Fantozzi
Alicia M. Fantozzi brings over 25
years of extensive expertise in project management and corporate
finance to the Mushrooms Inc. Business Development Team. As
Principal at ReGen, she has pioneered a seed-stage idea lab focused
on applied biophysics, igniting innovation in regenerative
technologies within water and agriculture sectors. With a trail of
accomplishments, Alicia held the position of Chief Financial
Officer at Resonant Technologies Group, propelling companies
specializing in physics-based technologies for health diagnostics,
immunotherapy, frequency-enabled agriculture, and material
sciences. As Principal at Strategic Advisory, her influence
extended to cross-border financial transactions, enhancing internal
data intelligence, cyber security, and risk management. She has a
proven track record in tax-structured finance and private equity,
originating multi-jurisdictional tax-optimized financings for
corporations and high-net-worth individuals. Alicia's remarkable
experience continues to drive Mushrooms Inc.'s growth in the
mushroom and psychedelic sectors.
About Dr. Hyder Khoja
Dr. Khoja, with over 22 years in
Functional and Psychedelic Medicine, is a leading voice in Drug
discovery and Developmental Science. He's developed treatments for
Non-Alcoholic fatty liver disease using "cannabinoids" and
"capsaicin", and partnered on a project extracting Chaga Mushrooms
for cancer treatment. Moreover, he's explored the potential of
lipids and "Beta-Carotene" from Algae and a cancer drug from
"Keyhole Limpet Hemocyanin (KLH)."
He founded "Transcendent Life Sci
and Emblem Nutraceuticals, Inc," focusing on "Coma Resurrection
Therapy" and the therapeutic benefits of psychotropic
compounds.
Dr. Khoja acquired his Ph.D. from
INP-ENSAT in 2003, trained at Michigan State University, and later
joined faculties like Virginia-Tech. His 2011 research on "Algae to
Biofuels" was lauded by the FAO-United Nations.
As the founder of "Transcendent Life
Sci and Emblem Nutraceuticals, Inc," his legacy resonates at the
intersection of science and transformation.
About
David Flores
David Flores brings a wealth of
visionary leadership to Mushrooms Inc.'s Business Development Team.
Guiding Psychedelic and Cannabis Convergence, David Flores, CEO
of
PSYC Corporation and its subsidiary,
Spotlight Media Corporation, is at the forefront of the
psychedelic and cannabis landscape. Over the past decade, David's
career has traversed legal, finance, and public markets. Based in
the San Gabriel Valley of California, he drives a multimedia empire
including
Psychedelic Spotlight,
Technical 420,
and
On The Bids.
David's journey began in legal and
financial sectors, culminating in his leadership role. Since July
2020, he has steered Psychedelic Spotlight and PSYC Corporation's
strategic growth. A former co-owner of a public and investor
relations firm in Las Vegas, NV, David built connections with
emerging companies in green energy and cannabis. His financial
acumen was shaped by roles at respected law firms, including
Greenberg Glusker LLP and Wood Smith Henning & Berman
LLP.
Beyond his professional pursuits,
David is a proud member of the LGBTQ+ community. He resides in West
Linn, OR, with his partner and Yorkshire terrier, reflecting a
multifaceted and visionary perspective.
Prior Press
Releases
Poised for Textile Innovation and Global Impact as Full Patent
Filing for Mycelium Thread Nears Completion
CEO, Kimberly Carlson, Discusses Exciting Potential of Industrial
Mushroom Industry on Psychedelic Spotlight Podcast
Announces Plan for Acquisitions and Vertically Integrated Business
Development by Partnering with diversified Mushroom Market
Leaders
Mushrooms, Inc. Announces Name and Ticker Symbol Change on OTC
Markets to "MSRM"
Safe
Harbor Statement
This
release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although we believe that the expectations
reflected in the forward-looking statements and the assumptions
upon which they are based are reasonable, we can give no assurance
or guarantee that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. The reader is cautioned not
to put undue reliance on these forward-looking statements, as these
statements are subject to numerous factors and uncertainties,
including but not limited to: adverse economic conditions,
competition, adverse federal, state and local government
regulation, international governmental regulation, inadequate
capital, inability to carry out research, development and
commercialization plans, loss or retirement of key executives and
other specific risks. To the extent that statements in this press
release are not strictly historical, including statements as to
revenue projections, business strategy, outlook, objectives, future
milestones, plans, intentions, goals, future financial conditions,
events conditioned on stockholder or other approval, or otherwise
as to future events, such statements are forward-looking, and are
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. The forward-looking
statements contained in this release are subject to certain risks
and uncertainties that could cause actual results to differ
materially from the statements made.
Corporate
Contact:
Mushrooms,
Inc.
CEO:
Kimberly
Carlson
Tel:
(877)
379-5400
email: info@mushroomsinc.com
Mushrooms (PK) (USOTC:MSRM)
Historical Stock Chart
Von Okt 2024 bis Nov 2024
Mushrooms (PK) (USOTC:MSRM)
Historical Stock Chart
Von Nov 2023 bis Nov 2024
